FDA Approves Gilead’s Bixlenvo to Simplify Regimens for Suppressed HIV Patients
The FDA has approved Bixlenvo, a once-daily single-tablet regimen from Gilead Sciences for adults with HIV whose virus is already suppressed. Combining bictegravir and lenacapavir, the drug targets patients unable to use existing one-pill options due to resistance or side effects. Priced at $4,595 per month, it offers a simplified alternative for those managing complex multi-drug regimens, with trials showing maintained viral suppression and no new safety concerns.